Overview
Employees
10001+
Founded date
1994
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 26, 2026 | Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standard | TIANJIN, China, Jan. 26, 2026 /PRNewswire/ -- In a landmark move for the cell therapy industry, a Device Master File (DMF) describing the first dedicated quality control standard for Mesenchymal Stromal Cells (MSCs) was accepted by the U.S.... |
| Apr 16, 2025 | Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy | SUZHOU, China, April 16, 2025 /PRNewswire/ -- April 12, 2025, Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has receive... |
| Mar 28, 2025 | Embarking on AI path with Chinese style | Guo Wei (second right), chairman of Digital China, and other panelists attend a seminar on global vision and enterprise innovation in the artificial intelligence era held at the University of Cambridge, United Kingdom, on March 13. CHINA DA... |
| Mar 24, 2025 | The Dawn of Precision in Liver Disease Management: HistoIndex's FibroSIGHT™ | In the ever-evolving landscape of healthcare, precision is the new gold standard. HistoIndex, a trailblazer in digital pathology, has taken a significant leap forward with the launch of FibroSIGHT™. This innovative Laboratory Developed Test... |
| Mar 18, 2025 | A chronographic analysis of MSC's rollercoasting journey | TIANJIN, China, March 18, 2025 /PRNewswire/ -- On March 12, 2025, China's Center for Drug Evaluation (CDE) approved Tasly's Investigational New Drug (IND) application for NR-20201, an allogeneic adipose-derived mesenchymal stromal cell, spa... |
| May 14, 2024 | Xinhua Silk Road: China's Tasly releases white paper, large model on TCM digital intelligence | BEIJING, May 14, 2024 /PRNewswire/ -- China's TCM product developer Tasly Pharmaceutical Group Co., Ltd. issued a white paper on digital intelligence of traditional Chinese medicine (TCM) and launched a related large model at an industrial ... |
| Jul 24, 2022 | Triastek and Eli Lilly partner to 3D print gastrointestinal drugs | Chinese drug 3D printing firm Triastek has announced a partnership with global pharmaceuticals company Eli Lilly to research and develop 3D printed oral drugs for the gastrointestinal tract. Specifically, the project will leverage Triastek’... |
| Mar 24, 2017 | China: C-Bridge backs pharma merger; Dadao closes Series B | Premium C-Bridge Capital and Tasly Holdings have invested $150 million in backing a merger of pharmaceutical firms in China. Meanwhile, Dadao Financial has closed a $29 million Series B round. C-Bridge Capital & Tasly Holdings invest $1... |
Reviews 0
FAQ about Tasly Holding Group
When was Tasly Holding Group founded?
Tasly Holding Group was founded in 1994.
What has the press written about Tasly Holding Group?
Parsers VC has collected 9 articles mentioning Tasly Holding Group, among them “Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standard” (Jan 26, 2026) and “Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy” (Apr 16, 2025).
Is Tasly Holding Group still active?
Yes, Tasly Holding Group is active; its latest activity on Parsers VC dates from Sep 17, 2026.